問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
莊志明
下載
2018-10-24 - 2024-03-31
Condition/Disease
Obesity
Test Drug
Semaglutide B 3.0 mg/mL PDS290 or Semaglutide placebo
Participate Sites6Sites
Recruiting4Sites
Terminated2Sites
Division of Cardiovascular Diseases
2022-12-05 - 2024-09-30
Prevention of Ischemic Stroke 、Acute Non-cardioembolic Ischemic Stroke、 High-risk Transient Ischemic Attack
AsundexianPlacebo (for Asundexian)ApixabanPlacebo (for Apixaban)
Participate Sites23Sites
Not yet recruiting2Sites
Recruiting20Sites
Terminated1Sites
全部